Header Logo

Connection

DAVID ROWLEY to Male

Back to Details
This is a "connection" page, showing publications DAVID ROWLEY has written about Male.
DAVID ROWLEY
Connection Strength
0.634
Male
  1. Androgen receptor variant-7 regulation by tenascin-c induced src activation. Cell Commun Signal. 2022 08 10; 20(1):119.
    View in: PubMed
    Score: 0.033
  2. ELF3 mediates IL-1a induced differentiation of mesenchymal stem cells to inflammatory iCAFs. Stem Cells. 2021 12; 39(12):1766-1777.
    View in: PubMed
    Score: 0.032
  3. Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.
    View in: PubMed
    Score: 0.020
  4. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A. 2014 Nov 18; 111(46):16389-94.
    View in: PubMed
    Score: 0.019
  5. WFDC1 is a key modulator of inflammatory and wound repair responses. Am J Pathol. 2014 Nov; 184(11):2951-64.
    View in: PubMed
    Score: 0.019
  6. Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. Am J Pathol. 2014 Jun; 184(6):1860-70.
    View in: PubMed
    Score: 0.019
  7. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013 Jun 15; 73(12):3716-24.
    View in: PubMed
    Score: 0.017
  8. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012 Dec; 19(6):R187-204.
    View in: PubMed
    Score: 0.017
  9. The WFDC1 gene: role in wound response and tissue homoeostasis. Biochem Soc Trans. 2011 Oct; 39(5):1455-9.
    View in: PubMed
    Score: 0.016
  10. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):200-10.
    View in: PubMed
    Score: 0.015
  11. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.015
  12. TGF-?1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. PLoS One. 2010 Oct 29; 5(10):e13751.
    View in: PubMed
    Score: 0.015
  13. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate. 2009 Mar 01; 69(4):373-84.
    View in: PubMed
    Score: 0.013
  14. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.013
  15. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology. 2008 Jul; 72(1):205-13.
    View in: PubMed
    Score: 0.012
  16. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene. 2008 Jan 17; 27(4):450-9.
    View in: PubMed
    Score: 0.012
  17. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005 Oct 01; 65(19):8887-95.
    View in: PubMed
    Score: 0.010
  18. Transforming growth factor-beta1 induced myofibroblasts regulate LNCaP cell death. J Urol. 2004 Dec; 172(6 Pt 1):2421-5.
    View in: PubMed
    Score: 0.010
  19. Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate. 2004 Oct 01; 61(2):182-91.
    View in: PubMed
    Score: 0.010
  20. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90.
    View in: PubMed
    Score: 0.010
  21. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate. 2004 Feb 15; 58(3):299-307.
    View in: PubMed
    Score: 0.009
  22. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.009
  23. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res. 2003 Sep 15; 63(18):5859-65.
    View in: PubMed
    Score: 0.009
  24. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002 Nov 01; 62(21):6021-5.
    View in: PubMed
    Score: 0.008
  25. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002 Sep; 8(9):2912-23.
    View in: PubMed
    Score: 0.008
  26. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients. Cells. 2022 07 29; 11(15).
    View in: PubMed
    Score: 0.008
  27. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002 Jun 01; 62(11):3298-307.
    View in: PubMed
    Score: 0.008
  28. Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Hum Pathol. 2022 04; 122:84-91.
    View in: PubMed
    Score: 0.008
  29. Reactive stroma in prostate cancer progression. J Urol. 2001 Dec; 166(6):2472-83.
    View in: PubMed
    Score: 0.008
  30. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001 Nov 01; 49(3):213-23.
    View in: PubMed
    Score: 0.008
  31. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021 02 15; 131(4).
    View in: PubMed
    Score: 0.008
  32. IP-10 and CXCR3 signaling inhibit Zika virus replication in human prostate cells. PLoS One. 2020; 15(12):e0244587.
    View in: PubMed
    Score: 0.007
  33. Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific. Oncogene. 2021 01; 40(3):693-704.
    View in: PubMed
    Score: 0.007
  34. The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers. Mamm Genome. 2000 Sep; 11(9):767-73.
    View in: PubMed
    Score: 0.007
  35. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924.
    View in: PubMed
    Score: 0.007
  36. Moving Beyond Gleason Scoring. Arch Pathol Lab Med. 2019 05; 143(5):565-570.
    View in: PubMed
    Score: 0.007
  37. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology. 1998 Aug; 139(8):3569-77.
    View in: PubMed
    Score: 0.006
  38. Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem. 1998 Mar; 46(3):379-88.
    View in: PubMed
    Score: 0.006
  39. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol. 1998 Mar; 10(3):355-63.
    View in: PubMed
    Score: 0.006
  40. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem. 1998 Feb 20; 273(8):4574-84.
    View in: PubMed
    Score: 0.006
  41. Replication of Zika Virus in Human Prostate Cells: A Potential Source of Sexually Transmitted Virus. J Infect Dis. 2018 01 30; 217(4):538-547.
    View in: PubMed
    Score: 0.006
  42. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 1998-1999; 17(4):411-9.
    View in: PubMed
    Score: 0.006
  43. Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
    View in: PubMed
    Score: 0.006
  44. Tenascin-C and Integrin a9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. Cancer Res. 2017 11 01; 77(21):5977-5988.
    View in: PubMed
    Score: 0.006
  45. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 2017 Jul 04; 8(27):44447-44464.
    View in: PubMed
    Score: 0.006
  46. Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3). Hum Pathol. 2017 05; 63:202-211.
    View in: PubMed
    Score: 0.006
  47. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.006
  48. Neuronal Trans-Differentiation in Prostate Cancer Cells. Prostate. 2016 10; 76(14):1312-25.
    View in: PubMed
    Score: 0.005
  49. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene. 2017 02 02; 36(5):618-627.
    View in: PubMed
    Score: 0.005
  50. Androgen-regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS-1). Endocrinology. 1996 Mar; 137(3):864-72.
    View in: PubMed
    Score: 0.005
  51. Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. Mol Cancer Res. 2016 Apr; 14(4):374-84.
    View in: PubMed
    Score: 0.005
  52. Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J Biol Chem. 1995 Sep 15; 270(37):22058-65.
    View in: PubMed
    Score: 0.005
  53. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences. Prostate. 2015 Oct; 75(14):1643-61.
    View in: PubMed
    Score: 0.005
  54. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res. 1995 Feb 15; 55(4):781-6.
    View in: PubMed
    Score: 0.005
  55. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.005
  56. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 2014 Jan 01; 20(1):100-9.
    View in: PubMed
    Score: 0.005
  57. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.005
  58. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013 Aug; 21(8):1611-20.
    View in: PubMed
    Score: 0.004
  59. Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Ann Clin Lab Sci. 2013; 43(1):11-21.
    View in: PubMed
    Score: 0.004
  60. Glucocorticoid regulation of transforming growth factor-beta activation in urogenital sinus mesenchymal cells. Endocrinology. 1992 Jul; 131(1):471-8.
    View in: PubMed
    Score: 0.004
  61. Application of the ICF to referral delay in total joint arthroplasty. Qual Saf Health Care. 2010 Dec; 19(6):e23.
    View in: PubMed
    Score: 0.004
  62. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009 Jun 15; 15(12):3979-89.
    View in: PubMed
    Score: 0.003
  63. Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Res. 2008 Jul 01; 68(13):5143-51.
    View in: PubMed
    Score: 0.003
  64. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res. 2007 Oct 15; 67(20):9613-5.
    View in: PubMed
    Score: 0.003
  65. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.003
  66. Properties of an intermediate-sized androgen receptor: association with RNA. Biochemistry. 1986 Nov 04; 25(22):6988-95.
    View in: PubMed
    Score: 0.003
  67. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.003
  68. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol. 2006 May; 168(5):1405-12.
    View in: PubMed
    Score: 0.003
  69. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72.
    View in: PubMed
    Score: 0.003
  70. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.003
  71. Molecular analysis of WFDC1/ps20 gene in prostate cancer. Prostate. 2004 Oct 01; 61(2):192-9.
    View in: PubMed
    Score: 0.002
  72. Effects of sodium molybdate on the androgen receptor from the R3327 prostatic tumor. Endocrinology. 1984 May; 114(5):1776-83.
    View in: PubMed
    Score: 0.002
  73. Molecular properties of the androgen receptor in rat ventral prostate. Ann N Y Acad Sci. 1984; 438:39-53.
    View in: PubMed
    Score: 0.002
  74. Androgen receptor binding characteristics in the cytosol of the rat dorsolateral prostate gland and the Dunning R-3327 prostatic adenocarcinoma. Prostate. 1984; 5(1):101-11.
    View in: PubMed
    Score: 0.002
  75. Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate. 2003 Jul 01; 56(2):98-105.
    View in: PubMed
    Score: 0.002
  76. Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology. 2003 Apr; 61(4):870-5.
    View in: PubMed
    Score: 0.002
  77. Monoclonal antibodies against the androgen receptor: recognition of human and other mammalian androgen receptors. Endocrinology. 1988 Jul; 123(1):601-10.
    View in: PubMed
    Score: 0.001
  78. A common molecular weight of the androgen receptor monomer in different target tissues. Biochemistry. 1987 Jun 02; 26(11):3174-82.
    View in: PubMed
    Score: 0.001
  79. Characterization of steroid receptors in human prostate using mibolerone. Prostate. 1986; 8(3):241-53.
    View in: PubMed
    Score: 0.001
  80. Structure and biochemistry of the Sertoli cell. Int Rev Cytol. 1985; 94:127-49.
    View in: PubMed
    Score: 0.001
  81. Exchange assay for androgen receptors in the presence of molybdate. J Steroid Biochem. 1984 Oct; 21(4):353-9.
    View in: PubMed
    Score: 0.001
  82. Affinity labeling of the androgen receptor in rat prostate cytosol with 17 beta-[(bromoacetyl)oxy]-5 alpha-androstan-3-one. Biochemistry. 1984 May 22; 23(11):2527-33.
    View in: PubMed
    Score: 0.001
  83. Physicochemical characterization of the androgen receptor from hyperplastic human prostate. Prostate. 1984; 5(6):567-79.
    View in: PubMed
    Score: 0.001
  84. Purification and characterization of the androgen receptor from rat ventral prostate. Biochemistry. 1983 Dec 20; 22(26):6170-5.
    View in: PubMed
    Score: 0.001
  85. Purification and characterization of androgen receptor from steer seminal vesicle. Biochemistry. 1982 Aug 17; 21(17):4102-9.
    View in: PubMed
    Score: 0.001
  86. Effects of estrogen upon the fine structure of epithelium and stroma in the rat ventral prostate gland. Invest Urol. 1979 Jul; 17(1):83-9.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.